ADC Therapeutics: $21.7M revenue, $14.7M R&D, quarter to Sep 2026
- ADC Therapeutics SA filed a 10-Q with the SEC on 9 Nov 2026 covering the period ending 30 Sep 2026: revenue $21.7 million (21,716,000 USD) and R&D spend $14.7 million (14,738,000 USD), which is 67.9% of that revenue; net income $-25,304,000 (-25,304,000 USD).
- These are the figures as tabulated from the filing.
- They are unadjusted, cover only the stated period, and say nothing about products, approvals or trials.
- R&D spend. $14.7 million (14,738,000 USD) · 67.9% of revenue
What happened
What changed
ADC Therapeutics SA filed a 10-Q with the SEC on 9 Nov 2026 covering the period ending 30 Sep 2026: revenue $21.7 million (21,716,000 USD) and R&D spend $14.7 million (14,738,000 USD), which is 67.9% of that revenue; net income $-25,304,000 (-25,304,000 USD).
Why it matters for pharma and investor readers
R&D spend against revenue is the plainest public measure of how much of a company's sales go back into the pipeline; the ratio here is computed from the two figures in the filing and is not compared with any prior period.
What the evidence supports
These are the figures as tabulated from the filing. They are unadjusted, cover only the stated period, and say nothing about products, approvals or trials.
- Filing. 10-Q · SEC EDGAR
- Company. ADC Therapeutics SA
- Period ending. 30 Sep 2026
- Revenue. $21.7 million (21,716,000 USD)
- R&D spend. $14.7 million (14,738,000 USD) · 67.9% of revenue
- Net income. $-25,304,000 (-25,304,000 USD)
Fields are copied from the primary record as published; ENCLAI has not independently verified them.
Where to learn more
Sources
- SEC filing: 0001628280-26-072178 (US SEC (EDGAR) · 2026-11-12)
Related briefings
Follow ENCLAI News
Get new briefings in your news reader. No ENCLAI account needed.
The daily disease brief
One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.